The death of a nurse from North Lanarkshire has been linked to the use of a weight-loss drug recently approved for use on the NHS. Susan McGowan, 58, took two low-dose injections of tirzepatide, known under the brand name Mounjaro, over the course of about two weeks before her death on 4 September.

A nurse has tragically died after receiving a weight loss injection in what is believed to be the first confirmed fatality linked to the drugs. Susan McGowan, 58, had taken two doses of Mounjaro, which makes people feel fuller sooner, before her death in September. The jabs are available on the NHS, but Ms McGowan purchased hers privately.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and content measurement, audience insights and product development. List of Partners (vendors)

Tirzepatide, known under the brand name Mounjaro is prescribed for type 2 diabetes, but has been shown in clinical trials to be effective for weight loss. It has been recommended as a weight loss drug for adults, with proposals for the phased launch of it on the NHS being set out by NICE.

A weight drug recently legalised in the UK contributed to the death of a 58-year-old nurse, according to a new report.

A nurse’s death has been linked to a weight loss drug which is approved for use on the NHS. Susan McGowan, 58, died on September 4 and had recently taken two doses of the weight loss jab Mounjaro. The drug,

Susan McGowan, 58, from Lanarkshire, died after taking two low-dose injections of tirzepatide, known under the brand name Mounjaro.